Skip to content

COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020

SARS-CoV-2 Seroconversion Study Among GHdC Staff Members

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04723290
Enrollment
2817
Registered
2021-01-25
Start date
2020-06-20
Completion date
2020-12-31
Last updated
2021-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been in contact with the SARS CoV-2 virus for organizational and evaluation purposes symptoms.

Detailed description

At the start of the SARS-CoV-2 pandemic, several workers had symptoms compatible with COVID-19 at a time when PCR (smear) testing was only allowed for hospitalized people. In addition, the PCR test has a fairly low sensitivity. In this context, serology can make it possible to determine whether the symptoms are indeed linked to exposure to SARS-CoV-2. As a hospital, and in order to prepare for a possible second epidemic wave, it is also useful to know the proportion of staff members who have already been in contact with the virus for organizational purposes and symptom assessment. .

Interventions

DIAGNOSTIC_TESTSerological tests for SARS Cov-2

Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Sponsors

Grand Hôpital de Charleroi
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Be a member of the staff of the Grand Hôpital de Charleroi who wishes to participate in order to know their immunity related to SARS CoV-2 after the first wave of pandemic.

Exclusion criteria

* Not be part of the staff of the Grand Hôpital de Charleroi.

Design outcomes

Primary

MeasureTime frameDescription
Serological tests to know the level of antibodies against SARS CoV-2up to 6 weeksThe hospital has organized several schedules and appointments for each staff member depending on the ability to analyze laboratory samples and blood draws.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026